BINEX Past Earnings Performance
Past criteria checks 0/6
BINEX's earnings have been declining at an average annual rate of -10.3%, while the Pharmaceuticals industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
-10.3%
Earnings growth rate
-10.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 6.5% |
| Return on equity | -7.2% |
| Net Margin | -8.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Subdued Growth No Barrier To BINEX Co., Ltd. (KOSDAQ:053030) With Shares Advancing 32%
Jul 01
BINEX Co., Ltd.'s (KOSDAQ:053030) 30% Share Price Plunge Could Signal Some Risk
Apr 17We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish Earnings
Mar 22BINEX Co., Ltd.'s (KOSDAQ:053030) Shares Climb 37% But Its Business Is Yet to Catch Up
Feb 26Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?
Mar 18If You Had Bought BINEX (KOSDAQ:053030) Stock A Year Ago, You Could Pocket A 253% Gain Today
Jan 28Are BINEX Co., Ltd.'s (KOSDAQ:053030) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Dec 24Revenue & Expenses Breakdown
How BINEX makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 136,335 | -12,165 | 51,956 | 1,255 |
| 31 Dec 23 | 154,825 | 4,671 | 53,805 | 1,310 |
| 30 Sep 23 | 160,785 | 2,845 | 56,346 | 2,246 |
| 30 Jun 23 | 168,715 | 13,451 | 55,821 | 1,928 |
| 31 Mar 23 | 169,566 | 17,625 | 53,973 | 1,821 |
| 31 Dec 22 | 156,677 | 12,445 | 50,866 | 1,618 |
| 30 Sep 22 | 154,969 | 16,511 | 48,513 | -153 |
| 30 Jun 22 | 148,847 | 16,354 | 46,793 | 5 |
| 31 Mar 22 | 137,081 | 12,565 | 46,070 | 181 |
| 31 Dec 21 | 134,399 | 19,094 | 45,916 | 384 |
| 30 Sep 21 | 129,474 | 10,144 | 45,087 | 1,174 |
| 30 Jun 21 | 129,031 | 9,390 | 45,622 | 1,157 |
| 31 Mar 21 | 134,424 | 13,278 | 44,277 | 1,112 |
| 31 Dec 20 | 132,976 | 6,412 | 44,486 | 1,097 |
| 30 Sep 20 | 131,550 | 13,970 | 43,387 | 1,104 |
| 30 Jun 20 | 129,097 | 11,463 | 42,953 | 1,121 |
| 31 Mar 20 | 127,064 | 8,735 | 43,956 | 1,092 |
| 31 Dec 19 | 125,259 | 8,504 | 43,179 | 1,035 |
| 30 Sep 19 | 122,942 | 13,092 | 40,635 | 1,009 |
| 30 Jun 19 | 119,099 | 13,565 | 40,408 | 1,000 |
| 31 Mar 19 | 111,203 | 8,878 | 40,394 | 945 |
| 31 Dec 18 | 104,043 | 6,337 | 39,297 | 895 |
| 30 Sep 18 | 91,167 | -4,232 | 40,651 | 785 |
| 30 Jun 18 | 84,136 | -9,325 | 39,074 | 658 |
| 31 Mar 18 | 79,031 | -12,419 | 35,551 | 660 |
| 31 Dec 17 | 78,026 | -10,797 | 34,419 | 622 |
| 30 Jun 17 | 80,782 | -7,528 | 30,512 | 704 |
| 31 Mar 17 | 81,500 | -3,065 | 29,823 | 761 |
| 31 Dec 16 | 80,924 | -3,144 | 29,053 | 818 |
| 30 Sep 16 | 77,576 | -12,169 | 29,469 | 885 |
| 30 Jun 16 | 74,890 | -10,196 | 27,535 | 956 |
| 31 Mar 16 | 71,804 | -9,553 | 26,417 | 1,043 |
| 31 Dec 15 | 66,539 | -9,289 | 24,324 | 1,169 |
| 30 Sep 14 | 56,724 | -2,357 | 21,231 | 1,404 |
| 30 Jun 14 | 58,746 | -3,158 | 21,328 | 1,682 |
| 31 Mar 14 | 59,260 | -3,099 | 20,956 | 1,877 |
| 31 Dec 13 | 57,297 | -4,069 | 20,834 | 2,181 |
| 30 Sep 13 | 60,440 | -6,533 | 19,130 | 1,867 |
Quality Earnings: A053030 is currently unprofitable.
Growing Profit Margin: A053030 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A053030 is unprofitable, and losses have increased over the past 5 years at a rate of 10.3% per year.
Accelerating Growth: Unable to compare A053030's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A053030 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22.7%).
Return on Equity
High ROE: A053030 has a negative Return on Equity (-7.17%), as it is currently unprofitable.